Targeting survivin via PI3K but not c-akt/PKB by anticancer drugs in immature neutrophils

Oncogene

Volumn 25, Issue 52, 2006, Pages 6915-6923

  Martinelli, S ^a   Kostylina, G ^a   Niggli, V ^a   Baumann, C ^a   Fey, M F ^a   Wendel, H G ^b   Lowe, S W ^b   Yousefi, S ^a   Simon, H U ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

Apoptosis; Cancer; Chemotherapy; Myelosuppression; Neutrophils; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER MODEL; CELL LINEAGE; CELL MATURATION; CELL TYPE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA CELL; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE MARROW; CELLS, CULTURED; DOXORUBICIN; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; LYMPHOMA; MICE; MICE, INBRED C57BL; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; NEUTROPHILS; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS; STEM CELLS;

EID: 33750581461     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209692     Document Type: Article

References (48)

1. Altznauer F, Martinelli S, Youse. S, Thürig C, Schmid I, Conway EM et al. (2004). J Exp Med 199: 1343-1354.
2. Ambrosini G, Adida C, Altieri DC. (1997). Nat Med 3: 917-921.
3. Andjelkovic M, Maira SM, Cron P, Parker PJ, Hemmings BA. (1999). Mol Cell Biol 19: 5061-5072.
4. Baumann R, Casaulta C, Simon D, Conus S, Yousefi S, Simon HU. (2003). FASEB J 17: 2221-2230.
5. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, Simoes-Wüst AP, Youse. S, Simon HU et al. (2005). Int J Cancer 117: 755-763.
6. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T et al. (2005). Cell 120: 747-759.
7. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. (2001). Mol Cell Biol 21: 952-965.
8. Bruno A, Conus S, Schmid I, Simon HU. (2005). J Immunol 174: 8090-8096.
9. Burgering BM, Coffer PJ. (1995). Nature 376: 599-602.
10. Carter BZ, Milella M, Altieri DC, Andreeff M. (2001). Blood 97: 2784-2790.
11. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL et al. (2003). Leukemia 17: 590-603.
12. Conus S, Bruno A, Simon HU. (2005). J Allergy Clin Immunol 116: 1228-1234.
13. Cowburn AS, Cadwallader KA, Reed BJ, Farahi N, Chilvers ER. (2002). Blood 100: 2607-2616.
14. Dahia PL, Aquiar RC, Alberta J, Kum JB, Caron S, Sill H et al. (1999). Hum Mol Genet 8: 185-193.
15. Dale D. (2003). Semin Oncol 30(4 Suppl 13): 3-9.
16. Daly C, Wong V, Burova E, Wei Y, Zabski S, Griffiths J et al. (2004). Genes Dev 18: 1060-1071.
17. Debatin KM. (2004). Cancer Immunol Immunother 53: 153-159.
18. Deveraux QL, Roy N, Stennicke HR, van Arsdale T, Zhou Q, Srinivasula SM et al. (1998). EMBO J 17: 2215-2223.
19. Fornaro M, Plescia J, Chheang S, Tallini G, Zhu YM, King M et al. (2003). J Biol Chem 278: 50402-50411.
20. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. (2003). Oncogene 22: 8983-8998.
21. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK et al. (1995). Cell 81: 727-736.
22. Fukuda S, Foster RG, Porter SB, Pelus LM. (2002). Blood 100: 2463-2471.
23. Fukuda S, Mantel CR, Pelus LM. (2004). Blood 103: 120-127.
24. Gardai SJ, Hildeman DA, Frankel SK, Whitlock BB, Frasch SC, Borregaard N et al. (2004). J Biol Chem 279: 21085-21095.
25. Herr I, Posovszky C, Di Marzio L, Cifone MG, Böhler T, Debatin KM. (2000). Oncogene 19: 4255-4262.
26. Hersey P, Zhang XD. (2003). J Cell Physiol 196: 9-18.
27. Kozikowski AP, Sun H, Brognard J, Dennis PA. (2003). J Am Chem Soc 125: 1144-1145.
28. Martinelli S, Urosevic M, Daryadel A, Oberholzer PA, Baumann C, Fey MF et al. (2004). J Biol Chem 279: 44123-44132.
29. McCormick F. (2004). Nature 428: 267-269.
30. McIlroy J, Chen D, Wjasow C, Michaeli T, Backer JM. (1997). Mol Cell Biol 17: 248-255.
31. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D et al. (2002). Oncogene 21: 5673-5683.
32. Murphy BM, O'Neill AJ, Adrain C, Watson RWG, Martin SJ. (2003). J Exp Med 197: 625-632.
33. Nicholson KM, Anderson NG. (2002). Cell Signal 14: 381-395.
34. Rich T, Allen RL, Wyllie AH. (2000). Nature 407: 777-783.
35. Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M. (1998). Blood 92: 3410-3415.
36. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). Science 304: 554.
37. Scheel-Toellner D, Wang K, Henriquez NV, Webb PR, Craddock R, Pilling D et al. (2002). Eur J Immunol 32: 486-493.
38. Scheid MP, Marignani PA, Woodgett JR. (2002). Mol Cell Biol 22: 6247-6260.
39. Scheid MP, Woodgett JR. (2003). FEBS Lett 546: 108-112.
40. Straka C, Oduncu F, Hinke A, Einsele H, Drexler E, Schnabel B et al. (2004). Blood 104: 1989-1994.
41. Suzuki J, Kaziro Y, Koide H. (1997). Oncogene 15: 1689-1697.
42. Uruno A, Sugawara A, Kanatsuka H, Kagechika H, Saito A, Sato K et al. (2006). Circulation 112: 727-736.
43. Vanhaesebroeck B, Waterfield MD. (1999). Exp Cell Res 253: 239-254.
44. Vivanco I, Sawyers CL. (2002). Nat Rev 2: 489-501.
45. Vong QP, Cao K, Li HY, Iglesias PA, Zheng Y. (2005). Science 310: 1499-1504.
46. Wang S, El-Deiry WS. (2004). Cancer Treat Res 119: 175-187.
47. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S et al. (2004). Nature 428: 332-337.
48. Zangemeister-Wittke U, Simon HU. (2004). Cell Cycle 3: 1121-1123.